Prudential Financial Inc. Sells 7,275 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Prudential Financial Inc. lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 223,288 shares of the biopharmaceutical company's stock after selling 7,275 shares during the quarter. Prudential Financial Inc. owned about 0.18% of Halozyme Therapeutics worth $10,675,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC increased its holdings in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust raised its position in shares of Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 1.2 %

Shares of HALO stock traded up $0.75 on Wednesday, reaching $62.62. The company had a trading volume of 223,423 shares, compared to its average volume of 1,376,117. The stock has a market cap of $7.74 billion, a PE ratio of 18.26, a PEG ratio of 0.42 and a beta of 1.32. The company has a 50-day moving average of $59.34 and a 200-day moving average of $54.84. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,200 shares of company stock worth $1,786,668 over the last ninety days. Company insiders own 2.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company lowered their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.